EWM
TBPH icon

Edge Wealth Management’s Theravance Biopharma TBPH Stock Holding History

Edge Wealth Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11
Closed -$1K – 451
2015
Q1 		$1K Buy
+11
New +$202 ﹤0.01% 422
2014
Q4 		– Sell
-22
Closed -$1K – 433
2014
Q3 		$1K Hold
22
– – ﹤0.01% 396
2014
Q2 		$1K Buy
+22
New +$662 ﹤0.01% 370

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

Edge Wealth Management's TBPH Position: Q2 2015 in Review

Edge Wealth Management sold out of Theravance Biopharma (TBPH) in Q2 2015, closing a stake of 11 shares — an estimated $1K sold.

Edge Wealth Management first reported a position in TBPH in Q2 2014 and held it in 3 quarters. The position peaked at $1K in Q1 2015. 90 funds tracked by Wall St. Rank hold TBPH as of Q2 2015.

  • Edge Wealth Management reported no remaining Theravance Biopharma position as of Q2 2015 after selling out during the quarter.
  • Edge Wealth Management sold 11 Theravance Biopharma shares in Q2 2015, an estimated $1K.
  • Edge Wealth Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 3 quarters.
  • Edge Wealth Management's Theravance Biopharma position peaked at $1K in Q1 2015.
  • 90 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2015.

Based on Edge Wealth Management's 13F filing for Q2 2015, filed 7 Jul 2015.